Novavax Announces Pricing of $18 Million Financing of Common Stock an... (ng made pursuant to an existing effectiv...)

Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants

Date:7/29/2008

ng made pursuant to an existing effective shelf registration statement and is being made directly by the Company. A prospectus supplement and the accompanying base prospectuses will be filed with the Securities and Exchange Commission and will be available on the SEC's website at http://www.sec.gov.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company creates VLPs by genetically engineering three-dimensional, nanostructures, which incorporate immunologically important lipids and recombinant proteins. Novavax' VLPs resemble a virus by lack the genetic material that would cause infection. Using the Company's proprietary VLP technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. The Company also utilizes a unique portable manufacturing system that allows for rapid production of vaccines requiring less infrastructure and represents a potential simpler and more efficient approach to vaccine production. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Novavax to Join Russell 3000 Index
2. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
3. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
4. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
5. Novavax Reports First Quarter 2008 Financial Results
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Opens Its First U.S. Vaccine Plant
8. Novavax CEO to Present at the World Vaccine Congress 2008
9. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
10. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
11. Novavax CEO to Present at BIO CEO & Investor Conference

Post Your Comments:

Novavax Announces Pricing of $18 Million Financing of Common Stock an...(ng made pursuant to an existing effectiv...)